Bilateral retrobulbar neuritis following cessation of ethambutol

Introduction: Ethambutol related ocular toxicity, is a well-documented fact. In spite of this a regular visual acuity examination is missed during treatment and follow-ups. Case Report: A 35-year-old male diagnosed with tuberculosis of spine, who was on antitubercular drugs for more than one year presented with complains of acute diminution of vision in both eyes two months following cessation of ethambutol. Visual electrode potential (VEP) showed prolongation of latency of P100 bilaterally based on which a diagnosis of ethambutol induced bilateral retrobulbar neuritis was made. Patient was started on intravenous methylprednisolone 1 g/day for three days which was followed by 11 days of oral steroids (1 mg/kg) which was tapered off over next 15 days. On follow-up patient showed signs of improvement in visual acuity and visual fields over the next six months. Conclusion: Visual symptoms may revert if prompt action is taken that include discontinuation of ethambutol and supplementation of pyridoxine along with steroids like in our case. Pharmacovigilance on patients receiving antitubercular drugs for exact dosage, drug combinations and duration is necessary to avoid untoward complications. (This page in not part of the published article.) International Journal of Case Reports and Images, Vol. 6 No. 2, Feburary 2015. ISSN – [0976-3198] Int J Case Rep Images 2015;6(2):76–80. www.ijcasereportsandimages.com Undrakonda et al. 76 CASE REPORT OPEN ACCESS Bilateral retrobulbar neuritis following cessation of ethambutol Vivekanand Undrakonda, Yashodhara B. M., Sarita Gonsalves, Shashikiran U., Smita Kapoor


INTRODUCTION
Acute onset of painless loss of vision in both eyes in a patient who is on antitubercular drugs pointing towards ethambutol toxicity, which is a well-documented fact. Ethambutol can affect the peripheral optic nerve fibers, causing defects in the peripheral visual field. Although optic neuritis is the most common side effect, retrobulbar neuritis is also a well-documented fact with involvement of either axial fibres or periaxial fibres [1,2].
Dose related ethambutol related retrobulbar neuritis in patients who received it for more than two months was reported as 18% in patients receiving >35 mg/kg/day, 5-6% with 25 mg/kg/day and <1% with 15 mg/kg/day [3].
Rarely, it can cause visible retinal manifestations, including hyperemia and swelling of the optic disc, flameshaped hemorrhages on the optic disc and in the retina, and macular edema. Other rarer side effects of ethambutol include peripheral neuropathy, cutaneous reactions (rash, pruritus, urticaria, etc.), thrombocytopenia and hepatitis [4].

CASE REPORT
A 35-year-old male presented to our ophthalmology outpatient department with chief complaints of marked painless diminution of vision (left eye > right eye) over a period of three days. His best corrected visual acuity recorded was 6/36 in right eye and 1/60 in left eye (Snellen chart). Gross observations of the anterior segments of both eyes were normal except for ill-sustained pupillary response to light in both eyes. Dilated fundoscopy was unremarkable.
One year back, he was diagnosed with tuberculosis of spine (thoracolumbar vertebra) based on a history of chronic cough, weight loss, backache, loss of appetite and results of diagnostic tests such as hemogram showed markedly elevated erythrocyte sedimentation rate (ESR) of 99 mm/hr, hematocrit of 36.2% with a bone scan with Tc-99m MDP which revealed multiple osteoblastic changes over T7 to T12 with multiple bilateral rib involvement. Following which a magnetic resonance imaging scan (plain and contrast) of lumbosacral spine showed features suggestive of diffusely infiltrating disease, with a possibility of multifocal tuberculosis in same region (Figure 1). Other parameters such as blood glucose, chest X-ray (Figure 2), liver function tests and renal function test were normal. Sputum test results were negative for acid-fast bacilli. The patient was started on antitubercular (ATT) drugs-isoniazid 300 mg/day, rifampicin 600 mg/day, pyrazinamide 1500 mg/day and ethambutol 1200 mg/day with vitamin B6 20 mg/day. Two months after initiation of ATT patient underwent a detailed ophthalmic examination which included visual acuity examination, macular function tests, and visual fields, all of which were unremarkable. After three months of initiation of ATT with four drugs, patient was advised to stop pyrazinamide and ethambutol and continue on two drugs isoniazid and rifampicin (which comes as combination tablet) as part of continuous phase treatment. The patient was lost to follow-up for next nine months. On repeat, consultation after one year patient was found to be still on isoniazid, rifampicin (combination tablet) and ethambutol, although he was advised to stop ethambutol three months after initiation of ATT. A repeat MRI scan of spine was performed after one year after initiation of ATT showed signs of improvement following which ethambutol was stopped and patient was advised to continue on isoniazid 300 mg/day, rifampicin 600 mg/day, and vitamin B6 20 mg/ day for 6 more months. Four months following stopping of ethambutol patient presented with gross diminution of vision in both eyes.

Investigations
Visual field assessment using Goldman perimeter showed presence of gross central visual field (CVF) defects with Red-green dyschromatopsia. Visual electrode potential (VEP) showed prolongation of latency of P100 bilaterally. Computed tomography scan of brain and MRI scan of optic nerve both with and without contrast were normal ( Figure 3). The cANCA was negative. A cerebrospinal fluid examination could not be performed.

Treatment
Based on the findings of VEP patient was started on intravenous methylprednisolone 1 g/day for three days which was followed by 11 days of oral steroids (1 mg/kg) which was tapered off over next 15 days.

Outcome and follow up
After one month, during review patient showed signs of improvement in visual acuity and visual fields. His visual acuity improved to 6/24 in right eye and 3/60 in left eye. Visual field assessment showed constriction in central visual field defects in the subsequent follow-ups.

DISCUSSION
Antitubercular drugs produce unwanted side effects, especially when used at high dosages and usually for periods of more than two months [5,6]. Retrobulbar neuritis, optic neuropathy and chiasmopathy due to ethambutol is a known neurotoxic complication. The onset of visual symptoms can occur within a period of 10 days to 90 days after initiation of therapy [7][8][9]. Detailed ophthalmoscopic examination reveals a bilateral and often an unequal decrease in visual acuity, loss of color vision, bitemporal hemianopsia or centrocecal scotoma on perimetry. Fundoscopy generally shows bilateral disc hyperemia with blurred borders. Rarely, fundoscopy may be normal like in our case report. Methylprednisolone along with cessation of the drug is considered useful, as was seen by the visual improvement in our patient. However, the recovery is often incomplete.
Visual acuity, contrast sensitivity, and multifocal ERG are sensitive tests to detect ethambutol toxicity in subclinical stages and hence very useful tools for monitoring patients under ethambutol therapy for ocular toxicity [10]. MRI scans of the optic nerves and chiasm, with normal findings in toxic and/or nutritional optic neuropathy, could be useful to differentiate between bilateral centrocecal scotomas and compressive or infiltrative lesions of the optic chiasm.
After three months of initiation of ATT with four drugs, our patient was instructed to stop pyrazinamide and ethambutol and continue on two drugs isoniazid and rifampicin which comes as combination tablet as part of continuous phase treatment for one year. But unfortunately, patient misunderstood the instructions as two tablets continued isoniazid, rifampicin which comes as a combination tablet with another tablet ethambutol for next nine months and was never on follow-up during this period.
After one year when our patient came for followup, he was instructed to stop ethambutol. Four months following discontinuation of ethambutol, which remains the mainstay of treating ethambutol-associated ocular toxicity, our patient developed bilateral retrobulbar neuritis.
Isoniazid associated combination formulations are easier to administer and also may reduce medication errors. These formulations are means of minimizing inadvertent monotherapy. It is quite common for patients with tuberculosis to be taking a variety of other medications, hence combination therapy is preferred to monotherapy to improve compliance in patients with comorbid conditions. The combination of rifampicin, isoniazid, ethambutol, and pyrazinamide for two months followed by combination of rifampicin and isoniazid for a total period of 6, 9, 12 or 18 months is the most frequent protocol used for treatment of spinal tuberculosis [11].
Early detection of adverse effects of drugs, failure of treatment and emergence of drug resistance due to non-compliance could be overcome by establishing a human bond between the patient and the provider through DOTs. In the developing world, evidence from uncontrolled studies shows that the introduction of DOTS has increased completion of therapy and cure rates from 25-50% (with unsupervised treatment) to 80-90%, with relapse rates of less than 5% [12,13]. Despite all the advantages of DOTS regimen, many orthopedic surgeons continue to give daily regimens. This is basically due to the fact that the efficacy of short-course intermittent therapy like DOTS regimen is not scientifically proven [14].
How could such complications be prevented: The first step is to identify patients in whom ethambutol is relatively contraindicated. These include patients who are unlikely to notice or describe visual symptoms, such as patients with dementia, mental retardation and children. Others include patients with pre-existing ophthalmological diseases with poor baseline vision. These patients should not be treated with ethambutol. The second step is to educate all patients treated with ethambutol on its side effects. Third step: Patients taking ethambutol should be instructed to discontinue the drug immediately at the onset of any visual symptoms and seek medical consult. Fourth step: When patients are prescribed combination therapy they should be closely monitored for compliance as well as side effects. The duration therapy for each drug should be defined and monitored. Physicians prescribing the drug should be aware of this and the drug should be used with proper patient education and ophthalmological monitoring especially when used in combination [15][16][17][18][19].
An immunological reason for bilateral retrobulbar neuritis was suspected and cANCA was performed to rule out other collagen vascular disorders and granulomatous conditions. Although few positive c-ANCA test results have been reported in patients with tuberculosis, Hodgkin's lymphoma, human immunodeficiency virus infection, nasal septal perforation, monoclonal gammopathies, and drug-induced Wegener-like disease. In this case, cANCA was negative [20][21]. Although the MRI scan showed no involvement of optic nerve, in view of positive VEP findings patient was started on methylprednisolone and oral steroids [22].

CONCLUSION
It is necessary that practitioners watch patients receiving antitubercular carefully for exact dosage, drug combinations and duration in order to avoid untoward complications. Visual symptoms may revert if prompt www.ijcasereportsandimages.com

Edorium Journals: An introduction
Edorium Journals Team

But why should you publish with Edorium Journals?
In less than 10 words -we give you what no one does.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day of every week of every month of every year.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial Review
All manuscripts submitted to Edorium Journals undergo pre-processing review, first editorial review, peer review, second editorial review and finally third editorial review.

Peer Review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early View version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates (minimum six times) about status of your manuscripts directly in your email.

Mentored Review Articles (MRA)
Our academic program "Mentored Review Article" (MRA) gives you a unique opportunity to publish papers under mentorship of international faculty. These articles are published free of charges.

Favored Author program
One email is all it takes to become our favored author. You will not only get fee waivers but also get information and insights about scholarly publishing.

Institutional Membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in fees make their research accessible to all.

Our presence
We have some of the best designed publication formats. Our websites are very user friendly and enable you to do your work very easily with no hassle.
We request you to have a look at our website to know more about us and our services.
We welcome you to interact with us, share with us, join us and of course publish with us.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Six weeks
You will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this by even one day, we will publish your manuscript free of charge.

Four weeks
After we receive page proofs, your manuscript will be published in the journal within four weeks (31 days).
If we fail to honor this by even one day, we will publish your manuscript free of charge and refund you the full article publication charges you paid for your manuscript.